TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI
Go back to TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI| TG THERAP (NASDAQ: TGTX) | Delayed: 53.22 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $53.22 | 52 Week High | $14.87 | |||
| Open | $53.22 | 52 Week Low | $4.90 | |||
| Day High | $53.22 | P/E | N/A | |||
| Day Low | $53.22 | EPS | $-0.67 | |||
| Volume | 19,256 | |||||
